Anti hla drbv711

Mononuclear cells were stained with ethidium monoazide (EMA, Sigma-Aldrich), anti-CD161-BV421, anti-CD16-V500, anti-CD8-BV605, anti-CD19-PECy5, anti-CD107a-PE (BD Biosciences), anti-TCRVα7.2-FITC, anti-CD3-AlexaFluor700 and anti-CD14-PE-Cy7 (Biolegend) on the day they were isolated from blood samples and liver biopsies. Anti-CD69-APC-Cy7 (Biolegend), anti-HLA-DR-BV711 and anti-CD107a-PE (BD Biosciences) were included to assess activation (CD69, HLA-DR) and degranulation (CD107a).
MAIT cells were identified as CD3⁺CD161⁺TCRVα7.2⁺ cells and studied in 35 paired blood samples and 32 paired liver biopsies prior to and at week 4 of antiviral therapy. Monocytes were identified as SSC^highHLA-DR⁺CD14⁺ cells and studied in 34 paired blood samples and 29 paired liver biopsies prior to and at week 4 of therapy. Liver biopsies with less than 41 events in the MAIT cell gate were excluded from analysis for activation and degranulation markers. CD14⁺⁺CD16⁻, CD14⁺⁺CD16⁺ and CD14⁺CD16⁺⁺ monocyte subsets were identified as described ^{31 (link)} and analyzed for activation marker expression if their event counts exceeded the 25^th percentile of the respective subset in all liver biopsies (n=33, 33, 23 and 23 events, respectively).